The challenge in prostate cancer (PCa) is to match the aggressiveness of the treatment to that of the cancer. Until recently, all screen-diagnosed localized cancers were considered at least potentially aggressive and in most cases were treated radically. Active surveillance represented a major step forward in acknowledging that some cancers were clinically insignificant and did not pose a threat to the patient’s life. Recently, a third option—focal therapy—has emerged as a potential middle ground between radical treatment and active surveillance. Read the article.
In recent years, various task forces or panels have come out strongly against using the PSA blood test as a screening tool. The latest was the Canadian Task Force on Preventive Health Care (CTFPHC) which, on Monday October 27th, 2014 stated that this test should not be used, as it does not prove to save lives!